Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.
Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Rigel Pharmaceuticals, Inc. today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. [More]
VolitionRx installs automated liquid handling system to increase rate of blood sample analysis

VolitionRx installs automated liquid handling system to increase rate of blood sample analysis

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced it has installed a Tecan EVO200 automated liquid handling system in its Namur, Belgium laboratory. [More]
Researchers gain rare insight into pregnancy-associated breast cancer

Researchers gain rare insight into pregnancy-associated breast cancer

During pregnancy, certain hormones trigger specialized mammary stem cells to create milk-producing cells essential to lactation. [More]
OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

OncoSynergy announced today that the FDA Office of Orphan Products Development has granted orphan drug designation for the investigational drug candidate OS2966, a neutralizing anti-CD29 monoclonal antibody, for the treatment of glioblastoma, the most common and deadliest primary adult brain tumor. [More]
Feist-Weiller, Caris Life Sciences partner to offer breakthrough technology to cancer patients

Feist-Weiller, Caris Life Sciences partner to offer breakthrough technology to cancer patients

Doctors at the LSU Health Shreveport Feist-Weiller Cancer Center will now have access to innovative, precision-medicine technology that determines the unique biological characteristics of each individual patient's cancer tumor. [More]
Researchers discover how arginine starvation specifically kills cancer cells

Researchers discover how arginine starvation specifically kills cancer cells

Researchers at UC Davis, City of Hope, Taipai Medical University and National Health Research Institutes in Taiwan have discovered how a drug that deprives the cells of a key amino acid specifically kills cancer cells. [More]
Seven physicians receive ASTRO grants to advance radiation oncology research

Seven physicians receive ASTRO grants to advance radiation oncology research

The American Society for Radiation Oncology has selected seven leading physicians to receive a total of $675,000 in awards and grants to advance radiation oncology research. The ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award will fund studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology. [More]
Complete analysis of the growing manufacturing market of HPAPIs and cytotoxic drugs

Complete analysis of the growing manufacturing market of HPAPIs and cytotoxic drugs

Reportbuyer.com has added a new market research report: HPAPIs and Cytotoxic Drugs Manufacturing Market, 2014 - 2024 [More]
Community-based program to focus on cancer care research and delivery

Community-based program to focus on cancer care research and delivery

Metro Detroit area residents with cancer, and those throughout Michigan, will have access to federally-funded cancer research studies thanks to a five-year grant recently awarded to the Beaumont Cancer Institute. Beaumont Health System is one of 34 community sites participating in the National Cancer Institute's Community Oncology Research Program, also known as NCORP. [More]
Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share. [More]
Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon Inc., a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules. [More]
Novogen receives funding support to commence studies in muscular dystrophy

Novogen receives funding support to commence studies in muscular dystrophy

The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company’s efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD). [More]
First-line sunitinib superior to everolimus for metastatic RCC

First-line sunitinib superior to everolimus for metastatic RCC

Results for the RECORD-3 trial support the current strategy of first-line sunitinib followed by second-line everolimus for the treatment of patients with metastatic renal cell carcinoma. [More]
Concordia subsidiary enrolls patients in Phase 2 trial to evaluate PDT with PHOTOFRIN in mesothelioma

Concordia subsidiary enrolls patients in Phase 2 trial to evaluate PDT with PHOTOFRIN in mesothelioma

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, enrolled the first patients in a randomized Phase 2 trial to evaluate Photodynamic Therapy (PDT) with PHOTOFRIN for patients with epithelioid malignant pleural mesothelioma (MPM). [More]

Chiltern earns Gold Membership in CDISC

Chiltern International Limited (Chiltern), a global contract research organization (CRO) has earned a Gold Membership in CDISC, the Clinical Data Interchange Standards Consortium. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan Inc. today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers. [More]
European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema. [More]
Breech births increase fetal mortality rate compared to elective vaginal delivery

Breech births increase fetal mortality rate compared to elective vaginal delivery

While a rise in cesarean section (C-section) delivery rates due to breech presentation has improved neonatal outcome, 40% of term breech deliveries in the Netherlands are planned vaginal deliveries. [More]
Jazz Pharmaceuticals offers $500 million aggregate principal amount of exchangeable senior notes

Jazz Pharmaceuticals offers $500 million aggregate principal amount of exchangeable senior notes

Jazz Pharmaceuticals plc today announced that Jazz Investments I Limited, its wholly-owned subsidiary, priced its previously announced offering of $500 million aggregate principal amount of exchangeable senior notes due 2021. [More]